相关实验视频

Updated: Jun 8, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

ERO1A水平是EGFR突变非小细胞肺癌的预后指标

M A Voronkova¹, B Johnson¹, N Gandhi²

¹West Virginia University Cancer Institute, Morgantown, WV, USA.

NPJ precision oncology

|November 4, 2024

概括

细胞内网膜氧化减排酶1α (ERO1A) 是EGFR突变非小细胞肺癌的不良预后指标. 切除ERO1A会影响瘤生长和奥西默提尼布的反应,这表明它在癌症进展中的作用.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

表皮生长因子受体 (EGFR) 突变的非小细胞肺癌 (NSCLC) 是癌症相关死亡的主要原因.
确定新的预后和治疗目标对于改善患者的治疗结果至关重要.

研究的目的:

为了研究内细胞网膜氧化还原酶1α (ERO1A) 作为EGFR突变NSCLC的预后指标的作用.
探索ERO1A对瘤进展和针对性治疗的反应的功能影响.

主要方法:

在EGFR突变NSCLC患者样本中分析ERO1A表达.
使用肺腺癌CPTAC数据集进行蛋白质组分析.
功能性研究涉及EGFR突变肺腺癌细胞系中的ERO1A剥离.
瘤生长的评估,克隆原性,以及对Osimertinib的反应.

主要成果:

ERO1A被确定为EGFR突变NSCLC的不良预后指标.
高的ERO1A表达与增加的分泌调节蛋白,细胞外矩阵组件和矩阵修饰酶相关.
切除ERO1A显著降低了瘤生长,克隆原性和球形形成在体外和体内.
ERO1A-Knockout细胞显示了拉米因玛2 (LAMC2) 和酸氧化酶样2 (LOXL2) 的分泌量减少.
ERO1A的消去影响了对奥西默提尼布的反应.

结论:

在EGFR突变NSCLC中,ERO1A在调节瘤微环境方面发挥着重要作用.
ERO1A有助于瘤进展,并可能代表治疗点.
向ERO1A可能会提高奥西默蒂尼布治疗的疗效.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...